| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.019 | 0.5 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.032 | 0.5 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |